MARKET

CLNNW

CLNNW

CLENE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8301
+0.0298
+3.72%
Closed 16:00 05/18 EDT
OPEN
0.7350
PREV CLOSE
0.8003
HIGH
0.9099
LOW
0.7350
VOLUME
20.74K
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
0.0450
MARKET CAP
--
P/E (TTM)
-0.5427
1D
5D
1M
3M
1Y
5Y
BRIEF-Clene Nanomedicine Presents Updated Blinded Efficacy Data From Ongoing Phase 2 Rescue-Als Study At Encals 2021 Annual Meeting
reuters.com · 6d ago
BRIEF-Clene Reports Q1 Loss Per Share Of $0.66
reuters.com · 05/11 13:00
BRIEF-Clene Inc Says Topline Data From A Phase 2 ALS Trial And Two Phase 2 Target Engagement Studies In MS And Parkinson's Disease Expected In H2 2021
reuters.com · 03/29 11:11
BRIEF-Clene Nanomedicine Announces Achievement Of 50% Enrollment In The Phase 3 Healey ALS Platform Trial
reuters.com · 03/09 15:00
BRIEF-Clene Says Cash On Hand As Of December 31, 2020 Was Approximately $59 Mln
reuters.com · 02/26 22:37
BRIEF-Clene Nanomedicine Presents Updated Interim Data From Phase 2 Multiple Sclerosis Programs At Actrims Forum 2021
reuters.com · 02/25 13:37
BRIEF-Clene Nanomedicine Initiates Phase 2 Study Of CNM-ZnAg For Patients With COVID-19
reuters.com · 02/16 12:39
BRIEF-Clene Nanomedicine Receives Patent Notice Of Allowance In United States For Using Gold Nanocrystals For Treatment Of Multiple Sclerosis
reuters.com · 01/19 13:17
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLNNW. Analyze the recent business situations of CLENE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About CLNNW
Clene Inc, formerly Chelsea Worldwide Inc., is a clinical-stage biopharmaceutical company. The Company through its subsidiary, Clene Nanomedicine, Inc., is focused on the development of therapeutics for neurodegenerative diseases. The Company has innovated a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. It has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The Company’s pipeline includes CNM-Au8, CNM-ZnAg, CNM-AgZn-17 and CNM-AuPt7. Its CNM-Au8 is a bioenergetic nanocatalyst, which enhances critical intracellular bioenergetic reactions necessary for repairing and reversing neuronal damage. CNM-AgZn17 is a topical gel polymer suspension of silver and zinc ions. Its CNM-PtAu7 is gold-platinum clean surfaced nanotechnology (CSN) therapeutic, which aims to address the unmet medical needs in several disease areas.

Webull offers kinds of Clene Inc. stock information, including NASDAQ:CLNNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLNNW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLNNW stock methods without spending real money on the virtual paper trading platform.